180 Day CGM for Diabetes: Eversense E3 Continuous Glucose Monitor

The Eversense E3 Continuous Glucose Monitoring (CGM) System gives real-time blood sugar readings every five minutes for people with diabetes. The system consists of an implantable fluorescence-based sensor, a transmitter, and a mobile app for displaying glucose values, trends and alerts on the patient’s compatible mobile device (smart phone, tablet, etc.).

The long-awaited FDA approval of Sensonics 180-day implantable continuous glucose monitor (CGM) – The Eversense E3 – is finally here. The new CGM is approved for people with diabetes who are 18 years old or older.

Senseonics is the medical technology company that created the implantable Eversense CGMs. In the fall of 2020, Senseonics partnered with Ascencia Diabetes Care (the maker of the Contour blood glucose meters), allowing Ascencia to handle the marketing and distribution of the Eversense products.